Skip to main content
Premium Trial:

Request an Annual Quote

PharmaStart Gets Kick With Industry/Academic Vet Martin

Premium

When David Martin left academia 20 years ago, he was worried that he would never be able to return after time in industry. So he made a deal: in three years, if he didn’t like the private sector, he would return to the groves of the University of California, San Francisco, where he’d been a professor of medicine and biochemistry. But until now, academia has never heard from Martin.

Martin, 62, recently teamed up with a brand-new consortium called Pharma-Start — a group of institutions led by SRI International and also comprised of Stanford, UCSD, UCSF, and the QB3 center — that aims to build a drug discovery and development pipeline out of academic work on potential targets. Martin, chairman of the consortium’s nine-member steering committee, says his personal goal is “to actually demonstrate that it is feasible without the participation of the biotech or the pharmaceutical industry … to take drug candidates into the clinic, into phase I or maybe early phase II.” That’s all pretty far off, though: at this point, basic organizational details are still being mapped out.

Martin comes to PharmaStart from Eos Biotechnology, which he cofounded and led as CEO for six years before its acquisition by Protein Design Labs. Before that he was CEO of Lynx Therapeutics and president of Chiron Therapeutics. He began his industry career working as head of R&D for Genentech and later DuPont Merck.

 

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.